P135 SARS-COV-2 infection in patients with cystic fibrosis

Balanetchi, L.; Gudumac, E.; Rotaru-Cojocari, D.; Selevestru, R.; Sciuca, S.

Introduction: Patients suffering from cystic fibrosis (CF) are more susceptible to recurrent or persistent pulmonary infections, which limit their lungs’ capacity and can endanger their life. The evolution of SARS CoV-2 infection inpatients with CF is a subject of interest and needs further research. Aim: Evaluation of clinical signs of SARS CoV-2 in patients with CF. Methods: We evaluated 3 patients with CF, who supported COVID-19 during the July 2020 - January 2021 period. Patients were tested by RT-PCR test when they presented symptoms. Results: The COVID-19 diagnosis has been confirmed in two male patients (7 and 10 years old) and a female patient of 30 years old. Fever, cough, and dyspnea were the common signs, which indicated an exacerbation of pulmonary infection. The child of 7 years with CF developed a mild form of infection and was treated at home, while the other two patients were admitted to hospital with severe infectious exacerbations. The hospitalised child developed SARS CoV-2 infection in the context of chronic infection with Pseudomonas aeruginosa and required O2-therapy due to decreased SpO 2 (92–93%). The adult woman with CF and chronic lung infection with Staphylococcus aureus showed a severe form of COVID-19 and pulmonary exacerbation. All the cases presented had a favorable evolution. Conclusions: The presence of comorbidities in patients with SARS CoV-2 is a major risk factor, and in CF patients with chronic pulmonary manifestations, infection with SARS CoV-2 infection support severe course of disease with intensive inpatient treatments.